Clinical Trials Logo

Clinical Trial Summary

ACTHAR gel has efficacy in the treatment of cutaneous sarcoidosis


Clinical Trial Description

Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung3, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis, ACTH is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Presently, corticosteroids as considered the drug of choice for the treatment of cutaneous sarcoidosis. However, ACTHER GEL not only has obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of cutaneous sarcoidosis. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02348905
Study type Interventional
Source Albany Medical College
Contact Haroon Chaudhry, MBBS
Phone 518-262-1542
Email chaudhh@mail.amc.edu
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date March 2015
Completion date January 2016

See also
  Status Clinical Trial Phase
Completed NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00373555 - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis N/A
Completed NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin Phase 2
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A
Recruiting NCT00470327 - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed NCT00512967 - The Occurence of Inflammation and Oxidative Stress in Lung Diseases N/A
Recruiting NCT01745237 - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed NCT00369980 - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT06396910 - TB and Sarcoidosis Granuloma
Completed NCT04156789 - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting NCT02916459 - EBUS-TBNA vs Flex 19G EBUS-TBNA N/A
Recruiting NCT02827734 - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed NCT02546388 - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01139710 - Sarcoidosis-associated Pulmonary Hypertension N/A
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4